oldjoe1
19 Mar 2015
Re: CLIN, present Broker Views <b>Clinigen Group PLC (CLIN) – Investment Analysts’ Weekly Ratings Updates</b>Posted on March 13, 2015, updated 18 March 2015, by Stefani Robinson in Analyst Articles - Company Sum, InvestingClinigen Group PLC logoSeveral analysts have recently updated their ratings and price targets for Clinigen Group PLC (LON: CLIN):3/11/2015 – Clinigen Group PLC had its “buy” ratingreaffirmed by analysts at N+1 Singer. They now have a GBX 590 ($8.89) price target on the stock.3/3/2015 – Clinigen Group PLC had its price target raised by analysts at Numis Securities Ltd from GBX 650 ($9.79) to GBX 770 ($11.60). They now have a “buy” rating on the stock.3/3/2015 – Clinigen Group PLC had its “hold” rating reaffirmed by analysts at Investec.2/27/2015 – Clinigen Group PLC had its “buy” rating reaffirmed by analysts at N+1 Singer. They now have a GBX 549 ($8.27) price target on the stock.2/11/2015 – Clinigen Group PLC had its “buy” rating reaffirmed by analysts at N+1 Singer. They now have a GBX 549 ($8.27) price target on the stock.2/11/2015 – Clinigen Group PLC had its “buy” rating reaffirmed by analysts at Oriel Securities Ltd. They now have a GBX 650 ($9.79) price target on the stock.2/3/2015 – Clinigen Group PLC had its price target raised by analysts at Investec from GBX 530 ($7.98) to GBX 546 ($8.22). They now have a “hold” rating on the stock.1/15/2015 – Clinigen Group PLC had its “buy” rating reaffirmed by analysts at N+1 Singer. They now have a GBX 500 ($7.53) price target on the stock.1/15/2015 – Clinigen Group PLC had its “buy” rating reaffirmed by analysts at Numis Securities Ltd. They now have a GBX 650 ($9.79) price target on the stock.Clinigen Group PLC (LON:CLIN) traded up 0.70% on Friday, hitting GBX 532.71. The stock had a trading volume of 29,042 shares. Clinigen Group PLC has a 52-week low of GBX 354.92 and a 52-week high of GBX 574.38. The stock has a 50-day moving average of GBX 524. and a 200-day moving average of GBX 500.. The company’s market cap is £439.76 million.Clinigen Group plc (LON:CLIN) is a specialty pharmaceuticals and services business company. The Company operates in three segments: Clinical Trial Supply, Specialty Pharmaceuticals and Global Access Programs. Clinical Trial Supply division is involved in the sourcing and supply of comparator products for Clinical Trials.
oldjoe1
06 Mar 2015
CLIN, present Broker Views CLIN present Broker Views........Date Broker Rec. Price Old target price New target price Notes06 Mar 15 N+1 Singer Buy 544.00 - - Retains03 Mar 15 Investec Hold 544.00 546.00 - Under Review03 Mar 15 Numis Buy 544.00 650.00 770.00 Reiterates27 Feb 15 N+1 Singer Buy 544.00 549.00 549.00 Retains18 Feb 15 Oriel Securities Buy 544.00 650.00 650.00 Reiterates
oldjoe1
05 Mar 2015
CLIN...Edison Broker Note.... Download full Edison Note from link.......[link]
oldjoe1
03 Mar 2015
Re: CLINIGEN, FANTASTIC RESULTS... 03 Mar 2015 Clinigen Group CLIN Numis Buy 552.00 550.00 650.00 770.00 ReiteratesSP TARGET 770p
oldjoe1
03 Mar 2015
Re: CLINIGEN, FANTASTIC RESULTS... Hardman and CO$CLIN Solid H1 from #Clinigen with sales +21% ex Fx, EBITDA +8%, EPS +13% and DPS +10%. Net cash gen to £12.9m.[link]
oldjoe1
03 Mar 2015
CLINIGEN, FANTASTIC RESULTS... <b>Clinigen Group plc: Half Year Revenues up 17% to £72.6m, Underlying EBITDA up 8% to £13.5m</b>03 Mar 2015 - 07
8[link] BURTON-ON-TRENT, England--(Business Wire)-- Clinigen Group plc (AIM: CLIN, Clinigen or the Group), the global specialty pharmaceuticals and pharmaceutical services business, has today published its half year results for the six months ended 31 December 2014.Financial highlightsGroup revenue up 17% to £72.6m (H1FY14: £61.8m); on a constant exchange rate basis up 21%Gross profit up 11% to £22.0m (H1FY14: £19.9m)Underlying EBITDA* up 8% to £13.5m (H1FY14: £12.5m), despite significant additional new product integration investmentAdjusted underlying earnings per share** up 12.6% to 12.5p (H1FY14: 11.1p). Reported earnings per share up 5.7% to 9.2p (H1FY14: 8.7p)Interim dividend up 10% to 1.1p per share (H1FY14: 1.0p per share)Net cash of £12.9m at 31 December 2014 (30 June 2014: £5.3m)Business highlightsCTS: 28% revenue growth, 14 new customers, underlying activity up (requests up 11%, medicines supplied up 13%)GAP: 51% increase in units shipped, seven new programs to start in CY15 including first program for AstraZeneca for their product CAZ-AVI. Fycompa program extended for a further 18 monthsSP: SP sales and gross profit up 21% driven by new products and underlying volume growth in Foscavir. Ethyol acquisition (August 2014) already contributing to revenues. Revitalisation plans for dexrazoxane portfolio of products, Cardioxane and Savene on track. Final Marketing Authorisations for Cardioxane transferred from Novartis, in February 2015.Underlying EBITDA is defined as earnings before interest, tax, depreciation and amortisation excluding share based payments and associated Employer`s National Insurance* Underlying earnings exclude share based payments, associated Employer`s National Insurance costs, amortization and are adjusted for associated taxPeter George, Chief Executive Officer, said:"After another strong first half, with all three divisions making good profit contributions, we are in a great position to continue our ambitious pursuit to become the world leaders in Clinical Trial Services, Global Access Programs and have a Specialty Pharmaceutical portfolio with 10 revitalized products."For the second half of the year gaining regulatory clearance for our dexrazoxane portfolio of drugs is a priority, along with the constant drive to convert the pipeline of new business and extend current customer relationships within CTS and GAP. In addition, we continue to explore opportunities to extend our global footprint and unlicensed supply market position."We anticipate another busy six months ahead."-Ends-For the full release, please visit the company website at www.clinigengroup.com
Prezza
05 Feb 2015
Re: Clinigen report from Edison Investment Nice post Danny , how can you sell these with such a good set of results.
dannysuko
16 Jan 2015
Clinigen report from Edison Investment Positive update from Edison research - Clinigen has reported a positive trading update that confirms progress is being maintained as expected. Clinigen operates in highly specialised and defensive niches that benefit from the pharmaceutical industry’s greater outsourcing of non-core functions. This, together with the rising regulatory burden and requirement for auditable supply chains, suggests the solid growth will continue. Our valuation is based on a number of parameters and the range is wide at £479-510m (580-618p a share), suggesting our current value of £495m (600p a share) has scope to rise over time.A steady share at these volatile times with a divi and genuine growth prospects. DSTrading update confirms progress is maintainedFirst half group revenues have grown by 17% to £72.6m, a 21% increase in constant currencies. The increase was driven mainly by a solid organic growth and new client wins in Clinigen CTS as well as maiden contributions from the new product acquisitions (Savene and Ethyol) in Clinigen SP. The gross profit is up around 11%, with group margins of around 30%, as all three operating businesses contributed positively to growth. The cash conversion has been particularly strong, with net cash more than doubling from £5.3m at 30 June 2014 to £12.9m at end December 2014.Building a portfolio of niche hospital-only productsThe integration of the new products appears to be going well, with confirmation that the revitalisation plans should begin to show through into revenue and, importantly, profit growth from FY16 onwards. Within Clinigen SP, Foscavir in-market sales were up 5% during the period, with future growth expected to track disease treatment activity (forecast at around 1-3% pa). Further product acquisitions are being evaluated, as are opportunities for broadening the geographic reach.Valuation: A range of £479-510m (580-618p a share)We value Clinigen using a combination of earnings-based metrics (P/E and EV/EBITDA), PEG ratio and a DCF valuation. The valuation range is wide at £479-510m (580-618p a share), with the simpler earnings metrics suggesting £479m (580p a share) using P/E and £507m (614p a share) on EV/EBITDA. Taking a longer-term view, the PEG ratio gives a value of £493m (598p a share) and the DCF-based method, based on conservative assumptions, yields a valuation of £510m (618p a share). The growth prospects suggest taking a simple mean of the range, £495m (600p a share), may be overly conservative.
lambrini girl
12 Jan 2015
Re: T1ps view on Acquistion SELL initial target £4..
zulu principle2
07 Jan 2015
Re: Drop today I don't think anything is wrong, just one of those days when a share drops, bit of profit taking or tree shake or something similar.Some figures2015 EPS Forecast 25.8p EPS Growth 35.8% PER 19.4 PEG 0.54 2016 EPS Forecast 31.4p EPS Growth 21.7% PER 15.9 PEG 0.73 The PER for 2015 is high so that may cause a few people to sell. I tend to look forward and 2016 PER is 16 which I am happy with. I may have to wait until 2015 results are out and people start to focus on 2016 for the price to move a lot.I'm happy it dropped it a bit as I wanted to make it one of my larger holdings and I picked up a few. If it drops a bit more I will pick up a few more.Jim Slater recommended it and the Zulu Principle is what I follow. He also knows a lot more than me and it will benefit from further recommendations in the same way Restore has.
penhome
07 Jan 2015
Re: Drop today I haven't managed to find any information anywhere on the drop today. Volume was limited. I wondered if MMs were trying to fill an order. No idea really.
NCMR
07 Jan 2015
Drop today Any insights?
oldjoe1
24 Nov 2014
Re: CLIN Broker Forecasts Coming In........ 24 Nov 2014 Clinigen Group CLIN Oriel Securities Buy 546.50 549.00 650.00 650.00 Reiterates
